Welcome to LookChem.com Sign In|Join Free

CAS

  • or

112661-85-5

112661-85-5

Post Buying Request

112661-85-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

112661-85-5 Usage

General Description

N-CBZ-5-aminolevulinic acid, also known as N-chlorobenzoyl-5-aminolevulinic acid, is a chemical compound that is used in medicinal and biochemical research. It is a derivative of 5-aminolevulinic acid, which is a precursor in the biosynthesis of tetrapyrroles such as heme and chlorophyll. N-CBZ-5-aminolevulinic acid has been studied for its potential as a photosensitizer in photodynamic therapy for cancer treatment, as well as for its role in photodynamic diagnosis of tumors. It is also used in the synthesis of various other bioactive compounds. The compound's ability to selectively accumulate in certain types of cells and tissues, as well as its phototoxic properties, make it a promising candidate for further research into its medical applications.

Check Digit Verification of cas no

The CAS Registry Mumber 112661-85-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,6,6 and 1 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 112661-85:
(8*1)+(7*1)+(6*2)+(5*6)+(4*6)+(3*1)+(2*8)+(1*5)=105
105 % 10 = 5
So 112661-85-5 is a valid CAS Registry Number.

112661-85-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-oxo-5-(phenylmethoxycarbonylamino)pentanoic acid

1.2 Other means of identification

Product number -
Other names 5-Benzyloxycarbonylamino-4-oxo-valeriansaeure

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:112661-85-5 SDS

112661-85-5Synthetic route

ALA
106-60-5

ALA

benzyl chloroformate
501-53-1

benzyl chloroformate

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Conditions
ConditionsYield
With sodium carbonate In 1,4-dioxane; water at 20℃; for 18h; pH=8 - 10;52%
In methanol at 0 - 20℃;
5-aminolevulinic acid hydrochloride
5451-09-2

5-aminolevulinic acid hydrochloride

benzyl chloroformate
501-53-1

benzyl chloroformate

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Conditions
ConditionsYield
With sodium hydroxide In 1,4-dioxane; water46%
With sodium hydroxide In 1,4-dioxane; water46%
With sodium hydrogencarbonate In water at 20℃; Cooling with ice;
5-amino-4-oxo-valeric acid-hydrochloride

5-amino-4-oxo-valeric acid-hydrochloride

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Conditions
ConditionsYield
With water; magnesium oxide; benzyl chloroformate
benzyl chloroformate
501-53-1

benzyl chloroformate

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: potassium carbonate / dichloromethane / 0.5 h / 0 °C
2: sodium hypochlorite; sodium dihydrogenphosphate / water; tert-butyl alcohol / 3 h / 0 °C
3: hydrogenchloride; iron / water / 1 h / 100 °C
View Scheme
C13H13NO5

C13H13NO5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Conditions
ConditionsYield
With hydrogenchloride; iron In water at 100℃; for 1h;
furan-2-ylmethanamine
617-89-0

furan-2-ylmethanamine

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: potassium carbonate / dichloromethane / 0.5 h / 0 °C
2: sodium hypochlorite; sodium dihydrogenphosphate / water; tert-butyl alcohol / 3 h / 0 °C
3: hydrogenchloride; iron / water / 1 h / 100 °C
View Scheme
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

caesium 5-(Cbz-amino)-4-oxopentanoate
1552321-93-3

caesium 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
With caesium carbonate In water100%
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

trichloroacetic acid
76-03-9

trichloroacetic acid

5-aminolevulinic acid 2,2,2-trichloroacetate

5-aminolevulinic acid 2,2,2-trichloroacetate

Conditions
ConditionsYield
With palladium 10% on activated carbon; hydrogen In methanol under 760.051 Torr; for 24h;92%
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

1-[2'-(hydroxy)ethyl]-2-ethyl-3-benzyloxy-4(1H)-pyridinone
210244-51-2

1-[2'-(hydroxy)ethyl]-2-ethyl-3-benzyloxy-4(1H)-pyridinone

2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate
1574379-22-8

2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 24h;87%
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 24h;87%
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 1-[2'-(hydroxy)ethyl]-2-ethyl-3-benzyloxy-4(1H)-pyridinone In dichloromethane at 20℃; Inert atmosphere;		77%
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 1-[2'-(hydroxy)ethyl]-2-ethyl-3-benzyloxy-4(1H)-pyridinone In dichloromethane; N,N-dimethyl-formamide at 20℃;		77%
3-(benzyloxy)-2-ethyl-1-(6-hydroxyhexyl)pyridin-4(1H)-one

3-(benzyloxy)-2-ethyl-1-(6-hydroxyhexyl)pyridin-4(1H)-one

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

6-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)hexyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-2-ethyl-1-(6-hydroxyhexyl)pyridin-4(1H)-one In dichloromethane at 20℃; Inert atmosphere;		80%
3-(benzyloxy)-1-(6-hydroxyhexyl)-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide

3-(benzyloxy)-1-(6-hydroxyhexyl)-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

6-(3-(benzyloxy)-2-(methylcarbamoyl)-4-oxopyridin-1(4H)-yl)hexyl-5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

6-(3-(benzyloxy)-2-(methylcarbamoyl)-4-oxopyridin-1(4H)-yl)hexyl-5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-1-(6-hydroxyhexyl)-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide In dichloromethane at 20℃; Inert atmosphere;		80%
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-1-(6-hydroxyhexyl)-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide In dichloromethane; N,N-dimethyl-formamide at 20℃;		80%
C20H27NO5

C20H27NO5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

2-(2-(2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethoxy)ethoxy)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

2-(2-(2-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)ethoxy)ethoxy)ethyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: C20H27NO5 In dichloromethane at 20℃; Inert atmosphere;		80%
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: C20H27NO5 In dichloromethane; N,N-dimethyl-formamide at 20℃;		70%
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one
739342-23-5

3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one

4-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)butyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

4-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)butyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-2-ethyl-1-(4-hydroxybutyl)pyridin-4(1H)-one In dichloromethane at 20℃; Inert atmosphere;		79%
benzyl 2-bromopropionate
3017-53-6

benzyl 2-bromopropionate

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

1-(benzyloxycarbonyl)ethyl 5-(Cbz-amino)-4-oxopentanoate
1552321-78-4

1-(benzyloxycarbonyl)ethyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
With triethylamine In ethyl acetate for 48h; Inert atmosphere; Reflux;77%
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

Benzyl 9-hydroxynonanoate

Benzyl 9-hydroxynonanoate

8-(benzyloxycarbonyl)octyl 5-(Cbz-amino)-4-oxopentanoate
1552322-00-5

8-(benzyloxycarbonyl)octyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
With 4-pyrrolidin-1-ylpyridine; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 72h; Inert atmosphere;77%
3-(benzyloxy)-2-ethyl-1-(8-hydroxyoctyl)pyridin-4(1H)-one

3-(benzyloxy)-2-ethyl-1-(8-hydroxyoctyl)pyridin-4(1H)-one

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

8-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

8-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)octyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-2-ethyl-1-(8-hydroxyoctyl)pyridin-4(1H)-one In dichloromethane at 20℃; Inert atmosphere;		75%
3-(benzyloxy)-2-ethyl-1-(12-hydroxydodecyl)pyridin-4(1H)-one

3-(benzyloxy)-2-ethyl-1-(12-hydroxydodecyl)pyridin-4(1H)-one

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

12-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)dodecyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

12-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)dodecyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-2-ethyl-1-(12-hydroxydodecyl)pyridin-4(1H)-one In dichloromethane at 20℃; Inert atmosphere;		73%
3-(benzyloxy)-2-ethyl-1-(10-hydroxydecyl)pyridin-4(1H)-one

3-(benzyloxy)-2-ethyl-1-(10-hydroxydecyl)pyridin-4(1H)-one

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

10-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)decyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

10-(3-(benzyloxy)-2-ethyl-4-oxopyridin-1(4H)-yl)decyl 5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: 3-(benzyloxy)-2-ethyl-1-(10-hydroxydecyl)pyridin-4(1H)-one In dichloromethane at 20℃; Inert atmosphere;		72%
tert-butyl (3-((1,7-dihydroxy-4-(3-hydroxypropyl)heptan-4-yl)amino)-3-oxopropyl)carbamate

tert-butyl (3-((1,7-dihydroxy-4-(3-hydroxypropyl)heptan-4-yl)amino)-3-oxopropyl)carbamate

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

4-(3-((5-(((benzyloxy)carbonyl)amino)-4-oxopentanoyl)oxy)propyl)-4-(3-((tert-butoxycarbonyl)amino)propanamido)heptane-1,7-diyl is[5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate]

4-(3-((5-(((benzyloxy)carbonyl)amino)-4-oxopentanoyl)oxy)propyl)-4-(3-((tert-butoxycarbonyl)amino)propanamido)heptane-1,7-diyl is[5-(((benzyloxy)carbonyl)amino)-4-oxopentanoate]

Conditions
ConditionsYield
Stage #1: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With dicyclohexyl-carbodiimide In dichloromethane; N,N-dimethyl-formamide at 20℃; for 0.833333h; Inert atmosphere;
Stage #2: tert-butyl (3-((1,7-dihydroxy-4-(3-hydroxypropyl)heptan-4-yl)amino)-3-oxopropyl)carbamate With dmap In dichloromethane; N,N-dimethyl-formamide at 20℃; for 25h; Inert atmosphere;		36.5%
16-hydroxyhexadecanoic acid
506-13-8

16-hydroxyhexadecanoic acid

5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

benzyl alcohol
100-51-6

benzyl alcohol

15-(benzyloxycarbonyl)pentadecyl 5-(Cbz-amino)-4-oxopentanoate
1552322-11-8

15-(benzyloxycarbonyl)pentadecyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
Stage #1: 16-hydroxyhexadecanoic acid; benzyl alcohol With toluene-4-sulfonic acid In toluene Reflux; Dean-Stark;
Stage #2: benzyl alcohol With sodium hydride at 100℃; for 3h; Inert atmosphere;
Stage #3: 5-(benzyloxycarbonylamino)-4-oxopentanoic acid With 4-pyrrolidin-1-ylpyridine; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 72h; Inert atmosphere;		0.57 g
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

4-(benzyloxycarbonyl)butyl 5-(Cbz-amino)-4-oxopentanoate
1552321-94-4

4-(benzyloxycarbonyl)butyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / water
2: sodium iodide / dimethyl sulfoxide / 100 °C / Inert atmosphere
View Scheme
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

5-(benzyloxycarbonyl)pentyl 5-(Cbz-amino)-4-oxopentanoate
1552321-96-6

5-(benzyloxycarbonyl)pentyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / water
2: sodium iodide / dimethyl sulfoxide / 48 h / 100 °C / Inert atmosphere
View Scheme
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

7-(benzyloxycarbonyl)heptyl 5-(Cbz-amino)-4-oxopentanoate
1552321-98-8

7-(benzyloxycarbonyl)heptyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: caesium carbonate / water
2: sodium iodide / dimethyl sulfoxide / 48 h / 100 °C / Inert atmosphere
View Scheme
5-(benzyloxycarbonylamino)-4-oxopentanoic acid
112661-85-5

5-(benzyloxycarbonylamino)-4-oxopentanoic acid

benzyl 2-bromo-2,2-difluoroacetate
155820-63-6

benzyl 2-bromo-2,2-difluoroacetate

(benzyloxycarbonyl)difluoromethyl 5-(Cbz-amino)-4-oxopentanoate
1552321-80-8

(benzyloxycarbonyl)difluoromethyl 5-(Cbz-amino)-4-oxopentanoate

Conditions
ConditionsYield
With triethylamine In acetonitrile for 18h; Reflux;6.7 g

112661-85-5Relevant articles and documents

PDT (photodynamics therapy) prodrug based on carbonylated polycaprolactone as well as preparation method and application of PDT prodrug

-

Paragraph 0040-0043, (2020/06/20)

The invention discloses a PDT (photodynamics therapy) prodrug based on carbonylated polycaprolactone. The structure of the PDT prodrug is represented in the description, wherein x is equal to 10-40, and y is equal to 10-40. The PDT prodrug based on carbonylated polycaprolactone is an amphiphilic polymer and can be prepared into micelles. A cell experiment proves that compared with pure 5-aminolevulinic acid, the content of the prodrug micelles converted into protoporphyrin is higher, and the prodrug has better destruction property on tumor cells. 5-aminolevulinic acid is introduced into functionalized polycaprolactone with a chemical grafting method, esterification of the 5-aminolevulinic acid is realized, lipid solubility and stability of 5-aminolevulinic acid are improved, and the prodrug has better targeting performance, higher conversion rate and better photodynamic effect.

Hydroxypyridinone and 5-Aminolaevulinic Acid Conjugates for Photodynamic Therapy

Battah, Sinan,Hider, Robert C.,MacRobert, Alexander J.,Dobbin, Paul S.,Zhou, Tao

, p. 3498 - 3510 (2017/05/05)

Photodynamic therapy (PDT) is a promising treatment strategy for malignant and nonmalignant lesions. 5-Aminolaevulinic acid (ALA) is used as a precursor of the photosensitizer, protoporphyrin IX (PpIX), in dermatology and urology. However, the effectiveness of ALA-PDT is limited by the relatively poor bioavailability of ALA and rapid conversion of PpIX to haem. The main goal of this study was to prepare and investigate a library of single conjugates designed to coadminister the bioactive agents ALA and hydroxypyridinone (HPO) iron chelators. A significant increase in intracellular PpIX levels was observed in all cell lines tested when compared to the administration of ALA alone. The higher PpIX levels observed using the conjugates correlated well with the observed phototoxicity following exposure of cells to light. Passive diffusion appears to be the main mechanism for the majority of ALA-HPOs investigated. This study demonstrates that ALA-HPOs significantly enhance phototherapeutic metabolite formation and phototoxicity.

PYRIDINONE COMPOUNDS FOR USE IN PHOTODYNAMIC THERAPY

-

Paragraph 0094, (2015/08/04)

A compound which is a compound of formula (I) or any salt thereof: wherein R1 is a Ci-C6 alkyl group, R2 is H or a Ci-C6 alkyl group, R3 is H or a Ci-C6 alkyl group, and n is an integer from 0 to 5.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 112661-85-5